14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 19, 2026
CORT vs MTNB: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 19, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CORT carries a Unified Composite Score of 43.9/100 (HOLD) at $64.98 (13.0x Forward P/E, 11.5% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin).
Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. CORT 43.9/100 HOLD), CORT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. 0.0% operating margin) and revenue trajectory (+64.0% vs. -100.0% YoY).
Technical & Structure Timing Caution: CORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Competes within the Biotechnology value chain with $979,904 market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ CORT vs MTNB Key Questions & Quantitative Answers
As of Nov 19, 2026, Corcept Therapeutics Inc. (CORT) is the stronger overall head-to-head candidate over Matinas BioPharma Holdings, Inc. (MTNB) in the Tradestie Institutional Equity Comparison Engine, winning 9–1 core matrix metrics and 5–0 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). CORT carries a Unified Composite Score of 43.9/100 (HOLD) at $64.98 (13.0x Forward P/E, 11.5% operating margin), whereas MTNB carries 54.6/100 (HOLD) at $0.81 (N/M Forward P/E, 0.0% operating margin). Composite vs. Pillar Nuance: While MTNB currently prints a higher short-term Unified Composite Score (54.6/100 HOLD vs. CORT 43.9/100 HOLD), CORT captures the overall institutional head-to-head verdict (9–1 matrix metrics and 5–0 across the 6 pillars) due to superior fundamental profitability (11.5% vs. 0.0% operating margin) and revenue trajectory (+64.0% vs. -100.0% YoY). Technical & Structure Timing Caution: CORT is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 21.7); meanwhile MTNB trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 33.0). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
CORT leads the Growth & Scale pillar: CORT posts +64.0% YoY revenue growth and +531.3% YoY earnings growth on $964M TTM revenue (98.5% gross margin, 11.5% operating margin), compared with MTNB at -100.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), CORT cumulative revenue shifted +204.0% while MTNB shifted N/A. In operating R&D and SG&A reinvestment, CORT deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for MTNB.
CORT screens cheaper on headline valuation multiples. CORT trades at 13.0x Forward P/E, 51.0x Trailing P/E, 0.81x PEG, and 7.6x EV/Revenue (20.2% FCF margin), whereas MTNB trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported cash flow margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against CORT (22.1% ROE) versus MTNB (-147.5% ROE) capital efficiency.
In options market volatility and institutional positioning, CORT carries 73.1% implied volatility (19th %ile, Compressed (<25th %ile)), a 1.76x (Put-Skewed) Put/Call open-interest ratio, DISTRIBUTION on-balance volume, and sits in a CONSOLIDATION options structure phase (1.62β · 81% Vol realized risk). By comparison, MTNB carries N/A implied volatility (N/A, Unclassified), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-7.20β · 147% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 19, 2026. For educational research only; not investment advice.